Founded Year



Acquired | Acquired

Total Raised


About Aidence

Aidence focuses primarily on the detection of lung cancer on X-ray / CT and MRI scans. Aidence provides radiologists with a software platform that automatically detects and classifies various disorders on multiple imaging modalities, using AI, for computers to read medical images and automatically provide structured reports.On January 24th, 2022, Aidence was acquired by RadNet. Terms of the transaction were not disclosed.

Aidence Headquarter Location

Keizersgracht 477E

Amsterdam, 1017,


+31 (0)6 2854 1275

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Aidence's Products & Differentiation

See Aidence's products and how their products differentiate from alternatives and competitors

  • Veye Lung Nodules

    Veye Lung Nodules is an AI-based solution for pulmonary nodule management on chest CT scans. It automatically detects, measures, classifies, and tracks the growth of pulmonary nodules as small as 3 mm. Veye delivers its analysis directly into the radiology workflow, as part of the original study. The solution is CE-marked as a class IIb medical device under the new EU Medical Device Regulation and can be used as a second or concurrent reader. It is currently running in routine practice and lung cancer screening programmes across Europe, analysing thousands of scans each week. Veye Lung Nodules supports the improvement of patient outcomes by delivering fast results, lowering the risk of misdiagnosis, and by detecting and segmenting possible early-stage lung cancer.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Expert Collections containing Aidence

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aidence is included in 7 Expert Collections, including Digital Health.


Digital Health

12,917 items

Startups recreating how healthcare is delivered


Artificial Intelligence

8,694 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

Aidence Patents

Aidence has filed 2 patents.

The 3 most popular patent topics include:

  • Artificial intelligence
  • Artificial neural networks
  • Machine learning
patents chart

Application Date

Grant Date


Related Topics



Artificial neural networks, Machine learning, Artificial intelligence, Medical imaging, 3D computer graphics


Application Date


Grant Date


Related Topics

Artificial neural networks, Machine learning, Artificial intelligence, Medical imaging, 3D computer graphics



Latest Aidence News

Local Diagnostic Companies Make Deals to Further Develop Tests to Detect Cancers

Feb 7, 2022

Two local diagnostic companies in recent weeks announced deals to further develop tests to detect cancers. Sawtelle-based RadNet Inc. announced Jan. 24 that it had acquired two unrelated Dutch technology companies: Aidence Holding B.V., a leading radiology artificial intelligence company focusing on pulmonary nodule management and lung cancer screening for between $40 million and $50 million, and Quantib B.V., which uses radiology artificial intelligence technology to detect prostate cancers and neurodegeneration, for $45 million. RadNet is the nation’s largest independent operator of onsite diagnostic imaging centers, with 350 sites in seven states. In May 2020, RadNet purchased Cambridge, Mass.-based Deep Health Inc., which had developed technology that uses artificial intelligence or “machine learning algorithms” to recognize suspicious masses in mammograms that could indicate breast cancer tumors. RadNet has since been integrating artificial intelligence technology into its diagnostic imaging services, particularly for mammography exams. Aidence’s technology analyzes thousands of computer tomography (CT) scans each week for customers in seven European countries including France, the Netherlands and the United Kingdom. In 2020, Aidence received a contract to help the U.K.’s National Health Service improve lung cancer prognosis; the company is deploying its technology into regional lung cancer screening programs in that nation. Meanwhile, in the U.S., Aidence submitted one of its technologies in December for U.S. Food and Drug Administration clearance for sale and use in the United States. Quantib has developed artificial intelligence technologies for analysis of prostate images and images detect brain abnormalities; it has customers in more than 20 countries. The company has already obtained FDA clearance for several of its artificial technology platforms that aid in analyzing diagnostic images. RadNet Chief Executive Howard Berger said in the announcement of both deals that Aidence’s technology will help address the under-utilization of lung screening in the U.S., while Quantib’s technology will reduce the cost of cancer screenings. “Artificial intelligence will have a transforming impact on diagnostic imaging and the field of radiology,” Berger said. “With the addition of Aidence and Quantib, we will now have effective screening solutions for the three most prevalent cancers. We believe that large-population health screening will play an important role for health insurers, health systems and large employer groups in the near future.” The other local company that announced a deal last month to further its cancer detection technology was Koreatown-based Nonagen Bioscience Corp. Nonagen has been developing a technology to analyze genetic material in blood samples to detect cancers, a process called liquid biopsy. The company’s first target is bladder cancer. At the root of Nonagen’s technology is an algorithm that analyzes 10 biological markers to both detect bladder cancer and to predict whether certain groups of patients with early-stage bladder cancer will respond to a bacterial therapy. In September, the FDA gave Nonagen’s algorithm a breakthrough device designation for its ability to predict whether the bladder cancer responds to that bacterial therapy. On Jan. 27, Nonagen announced it struck a deal with Saratoga Springs, N.Y.-based Peregrine Market Access in which Peregrine will market and brand Nonagen’s Oncuria liquid biopsy diagnostic test for bladder cancer. Peregrine specializes in helping bioscience companies commercialize their therapies, medical devices and other technologies. “After an extensive search for the right commercialization partner, we are confident that Peregrine Market Access is the optimal choice to help us succeed in bringing Oncuria to market,”  Charles Rosser, Nonagen’s chief executive, said in the announcement. The announcement characterized the deal as a “multiyear, multimillion-dollar agreement,” but did not disclose more specific terms. For reprint and licensing requests for this article, CLICK HERE . Read Our Newsletter (FREE)

Aidence Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aidence Rank

You May Also Like

Aidoc Medical

Aidoc finds and flags critical findings in medical images. By automatically prioritizing urgent, life-threatening conditions like intracranial hemorrhage and pulmonary embolism, Aidoc saves lives, improves patient care and cuts waiting time for the must urgent patients down to only a few minutes. The always-on AI integrates into a radiologist's workflow, reprioritizing cases without forcing radiologists to change the way they work.

Ultromics Logo

Ultromics is a global health technology company that provides autonomous echocardiography analysis through AI solutions – empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease. Its cloud-based service, EchoGo, uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

Kheiron Medical Technologies

Kheiron Medical Technologies is a healthcare software company. Through its Machine Learning technology, it seeks to makes cancer diagnoses faster, easier, cheaper and more accurate. Its Deep Learning algorithms analyze medical images and its software uses the analysis results to enable the automation of radiology reporting tasks.

VoxelCloud Logo

VoxelCloud utilizes artificial intelligence and cloud-computing technologies to provide automated medical image analysis and clinical decision support for medical practitioners. VoxelCloud aims to provide accurate, accessible, and personalized medical image analysis by building medical image knowledge graph based on medical semantics and multiple artificial intelligence models.


12 SIGMA is a biotechnology company that integrates artificial intelligence and deep learning into modern medical image diagnosis and medical data analysis. 12SIGMA is based in Beijing and San Diego.

Infervision Logo

Infervision is a global high-tech enterprise in medical artificial intelligence, aiming to empower doctors with higher efficiency and benefit patients with better diagnosis, outcome, and lower cost. Infervision provides products and services to providers, and patients; with robust A.I. solutions fully integrated with the healthcare workflow to help diagnosing various diseases and conditions such as cerebral hemorrhage, lung cancer, bone fractures, emphysema, and more. Infervision also provides an AI-powered research platform for medical professionals with any research directions and needs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.